CA-SPIRENT
Spirent Communications plc (LSE:SPT), a world leader in lifecycle service assurance solutions, today announced it has completed the first phase of a multi-million dollar VisionWorks Customer Experience Assurance (CEA) solution deployment for a tier-1 North American service provider. The deployment, valued in the range of $6M, consists of proactive and automated troubleshooting analytics for identifying, prioritizing, and resolving customer experience issues. Multiple additional phases are planned over the next 12 months.
With the VisionWorks CEA solution, providers are able to shift away from manual problem resolution driven by customer complaints to proactive, automated resolution, resulting in a better customer experience at a much lower cost. VisionWorks CEA aggregates data across network databases and assurance systems to create a unified view of the customer’s experience and the underlying network performance factors impacting it. VisionWorks CEA is able to proactively highlight and resolve issues affecting many customers before downstream care and other costs are incurred. When unavoidable problems occur, VisionWorks significantly accelerates the troubleshooting process by rapidly pinpointing root causes and triggering resolutions. VisionWorks CEA is unique in its ability to leverage synthetic traffic from test agents to flush out and fix issues before a single customer is impacted.
“We see demand for proactive, automated customer experience assurance and analytics as a key driver for our Lifecycle Service Assurance business,” said Dave Stehlin, General Manager of Lifecycle Service Assurance at Spirent. “As an example, during the recent natural disasters in North America, VisionWorks CEA helped our customers prioritize their troubleshooting activities so they could restore critical services to their customers as fast as possible. As virtualization and 5G are adopted, analytics will be an essential tool for efficiently assuring customer experience and managing service issues, whether large scale or customer-specific.”
The VisionWorks CEA solution is part of a suite of Lifecycle Service Assurance (LSA) solutions from Spirent. Spirent LSA solutions automate testing and assurance workflows across the service lifecycle, accelerating service innovation and reducing operational costs. To learn more about Lifecycle Service Assurance and VisionWorks, please visit https://www.spirent.com/Solutions/Service-Assurance .
About Spirent Communications plc
Spirent Communications plc
(LSE: SPT), a global leader in test and measurement, offers an extensive
portfolio of solutions to test data centers, cloud computing and
virtualized environments, high speed Ethernet networks and services,
wireless networks and devices, network and application security, and
positioning technologies. For more information, visit https://corporate.spirent.com/About-Us
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171010005633/en/
Contact:
Americas:
SS PR
John Nelson, +1 847 415 9081
spirent@sspr.com
or
Asia
Pacific:
Spirent Communications
Janet Peng, +86 (10) 82330055,
x160
janet.peng@spirent.com
or
Europe:
Spirent
Communications
Simon Loe, +44 (0) 7850 205885
simon.loe@spirent.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom